Ignite Creation Date:
2025-12-26 @ 10:57 AM
Ignite Modification Date:
2026-02-27 @ 6:45 PM
Study NCT ID:
NCT02688608
Status:
COMPLETED
Last Update Posted:
2022-02-10
First Post:
2016-01-20
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
Sponsor:
Saad A Khan
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-10
Start Date Type:
None
Primary Completion Date:
2020-10
Primary Completion Date Type:
ACTUAL
Completion Date:
2021-10
Completion Date Type:
ACTUAL
First Submit Date:
2016-01-20
First Submit QC Date:
None
Study First Post Date:
2016-02-23
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-12-08
Results First Submit QC Date:
None
Results First Post Date:
2022-02-10
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-02-08
Last Update Post Date:
2022-02-10
Last Update Post Date Type:
ACTUAL